Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial

IMPORTANCE: Preliminary cost-effectiveness analyses of proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) were based on benefits estimated from reductions in low-density lipoprotein cholesterol that occurred in PCSK9i trials with variable results. The recent Further Cardiovascular Outc...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:JAMA Cardiol
Autori principali: Arrieta, Alejandro, Hong, Jonathan C., Khera, Rohan, Virani, Salim S., Krumholz, Harlan M., Nasir, Khurram
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Medical Association 2017
Soggetti:
Brief Report
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5814995/
https://ncbi.nlm.nih.gov/pubmed/29049467
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2017.3655
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi